How big is The Beauty Health Co.?

As of Jun 18, The Beauty Health Co. has a market capitalization of 192.80 million and reported net sales of 322.47 million with a net profit of -38.52 million over the latest four quarters. The balance sheet shows shareholder's funds of 51.80 million and total assets of 685.68 million.

As of Jun 18, The Beauty Health Co. has a market capitalization of 192.80 million, categorized as a Micro Cap.<BR><BR>As of Jun 18, the company reported net sales of 322.47 million for the latest four quarters, while the net profit for the same period was -38.52 million.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 51.80 million and total assets amounting to 685.68 million.

What does The Beauty Health Co. do?

The Beauty Health Co. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $70 million and a net loss of $10 million as of March 2025. It has a market cap of $192.80 million, with key metrics indicating significant financial challenges.

Overview: <BR>The Beauty Health Co. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 70 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 192.80 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 4.02 <BR>Return on Equity: -94.21% <BR>Price to Book: 4.19<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold The Beauty Health Co.?

Is The Beauty Health Co. overvalued or undervalued?

As of May 10, 2023, The Beauty Health Co. is considered overvalued and risky, with poor financial metrics such as a Price to Book Value of 4.38 and negative ROCE and ROE ratios, despite a year-to-date return of 49.06% that underperformed the S&P 500's 12.22%.

As of 10 May 2023, the valuation grade for The Beauty Health Co. moved from attractive to risky, indicating a shift towards a more negative outlook. The company is currently overvalued, as evidenced by its Price to Book Value of 4.38 and negative ratios such as EV to EBIT at -6.16 and EV to EBITDA at -12.23. These metrics suggest significant financial distress, particularly highlighted by a ROCE of -27.18% and an ROE of -94.21%.<BR><BR>In comparison to its peers, The Beauty Health Co. has a less favorable EV to EBITDA ratio than Paragon 28, Inc. at -52.8268 and SI-BONE, Inc. at -25.8938, both of which also reflect risky valuations. Despite a strong year-to-date return of 49.06%, the company has underperformed the S&P 500 over the same period, which returned 12.22%. This stark contrast in performance underscores the challenges facing The Beauty Health Co. and reinforces its current overvaluation status.

Is The Beauty Health Co. technically bullish or bearish?

As of September 11, 2025, The Beauty Health Co. has shifted to a bullish trend supported by positive technical indicators, despite a bearish monthly RSI, and has achieved a year-to-date return of 49.06%, outperforming the S&P 500's 12.22%.

As of 11 September 2025, the technical trend for The Beauty Health Co. has changed from mildly bullish to bullish. The current technical stance is bullish, with key indicators supporting this position including a bullish MACD on the weekly timeframe, bullish daily moving averages, and a bullish signal from Bollinger Bands on the monthly timeframe. However, the RSI on the monthly is bearish, indicating some caution. <BR><BR>In terms of performance, the company has shown a strong year-to-date return of 49.06%, significantly outperforming the S&P 500's 12.22% return, although it has underperformed over longer periods, particularly in the 3-year and 5-year returns.